GNMX - Aevi Genomic Medicine, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.15
+1.15 (+-2.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.18
Open1.18
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.13 - 1.21
52 Week Range0.98 - 6.20
Volume440,065
Avg. Volume482,279
Market Cap68.232M
Beta0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.97
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • PR Newswire13 days ago

    Aevi Genomic Medicine Announces New Appointment to its Board of Directors

    PHILADELPHIA, Dec. 4, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today the appointment of Matthew D. Bayley, MD, MBA to its Board of Directors. "We are excited to welcome Matt to our Board of Directors during this important time for the Company," said Mike Cola, CEO of Aevi Genomic Medicine. Dr. Bayley currently serves as a Senior Vice President and Chief Strategy Officer at the Children's Hospital of Philadelphia (CHOP) where he leads strategic planning and business development efforts and supports the CEO in developing the strategy of advancing CHOP's mission.  Prior to joining CHOP, he was a Partner at McKinsey & Company, a global management consulting firm, where his work focused on strategy, operations, and organizational topics in the healthcare field.  Dr. Bayley graduated from the University of Virginia's McIntire School of Commerce, and went on to receive his M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School.

  • Zacks Small Cap Researchlast month

    GNMX: Still Expect ADHD Data Mid-2018, Could Be Next Value-Inflection Point

    Aevi (GNMX) reported financial results for their third quarter on November 2nd.  The operational update mostly relates to timelines of the various ongoing studies – while this includes an anticipated slight delay to the anti-LIGHT signal finding study in pediatric onset Crohn’s, it appears status of the two AEVI-001 programs (ADHD and ASD) remain largely inline with earlier expectations. Cash used in operating activities was $6.4M and $24.9M ($7.7M and $24.8M, ex-changes in working capital) in Q3 and the first nine months of 2017, respectively.  Cash balance at quarter-end was $15.0M but pro-forma for net proceeds from the equity sale in October (details below), cash balance was approximately $42M - which represents ~17 months (5 – 6 quarters) of operating capital at the current burn rate.  The company expects current cash to be sufficient to fund operations into 2019 – by that time they should have announced initial data from AEVI-001 phase II in ADHD and, possibly from AEVI-001 in pediatric onset Crohn’s (i.e.

  • PR Newswire2 months ago

    Aevi Genomic Medicine Reports Third Quarter 2017 Financial Results

    PHILADELPHIA , Nov. 2, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended September 30, 2017 and provided ...

  • PR Newswire2 months ago

    Aevi Genomic Medicine Announces Completion of $28 Million Private Placement

    PHILADELPHIA, Oct. 17, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX)(the "Company") today announced the completion of a previously announced private placement of 22.2 million shares of its common stock with warrants to purchase approximately 4.0 million additional shares of its common stock, for aggregate proceeds of $28.0 million, before expenses (the "PIPE"). The Children's Hospital of Philadelphia Foundation (the "CHOP Foundation") was the lead investor, with additional participation by other blue-chip investors. The CHOP Foundation has committed to provide up to an additional $5.0 million of equity financing through June 30, 2018, subject to certain terms and conditions.

  • Is Aevi Genomic Medicine Inc (GNMX) Undervalued?
    Simply Wall St.3 months ago

    Is Aevi Genomic Medicine Inc (GNMX) Undervalued?

    Aevi Genomic Medicine Inc (NASDAQ:GNMX), a pharmaceuticals, biotechnology and life sciences company based in United States, View our latest analysis for Aevi Genomic Medicine Is GNMX still cheap? Great newsRead More...

  • PR Newswire3 months ago

    Aevi Genomic Medicine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

    PHILADELPHIA, Sept. 5, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 19th Annual Global Investment at 2:35 PM EDT in New York, NY on Monday, September 11, 2017 at the Lotte New York Palace Hotel in New York, NY. Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies.

  • Zacks Small Cap Research4 months ago

    GNMX: AEVI-001 Data Mid-2018, Next Value Inflection Point?

    Cash used in operating activities was $7.9M and $18.5M ($7.2M and $17.1M, ex-changes in working capital) in Q2 and 1H 2017, respectively.  Management anticipates that the quarter-end cash balance, of $21.4M, is sufficient to fund operations until ~mid-2018, at which point they also expect to have reported topline data from the recently initiated ADHD/CNTN4+ phase II trial and initial data from a too-be-initiated proof-of-concept study for their anti-LIGHT candidate in pediatric Crohn's. Relative to the operational update, study designs and timelines were unveiled for the phase II mGluR/CNTN4+ADHD study and for a proof-of-concept II CNTN4+ASD study.  The current game-plan includes somewhat of a parallel approach with the AEVI-001 program (i.e.

  • PR Newswire4 months ago

    Aevi Genomic Medicine Announces Agreement for $28 Million Private Placement

    PHILADELPHIA, Aug. 10, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the "Company") today announced the execution of a definitive agreement to sell shares of common stock and warrants to purchase common stock in a private placement, or PIPE, to certain accredited investors, led by Children's Hospital of Philadelphia Foundation ("the CHOP Foundation"). The Company will sell 22.2 million shares of its common stock with warrants to purchase approximately 4.0 million additional shares of its common stock, for aggregate proceeds of $28.0 million, before expenses. The CHOP Foundation led the financing, with additional participation by other undisclosed existing blue-chip investors.

  • PR Newswire4 months ago

    Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results

    PHILADELPHIA , Aug. 9, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended June 30, 2017 and provided ...

  • PR Newswire6 months ago

    Aevi Genomic Medicine to Present at the JMP Securities Life Sciences Conference

    PHILADELPHIA, June 13, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will be a participant on ...

  • Accesswire7 months ago

    Blog Coverage: Aevi Genomics Announces Phase 2 Clinical Trial and Reports Q1 2017 Results

    Upcoming AWS Coverage on Juno Therapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / May 11, 2017 / Active Wall St. blog coverage looks at the headline from Aevi Genomic Medicine, Inc. (NASDAQ: GNMX ...

  • Accesswire7 months ago

    Investor Network: Aevi Genomic Medicine, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 10, 2017 / Aevi Genomic Medicine, Inc. (NASDAQ: GNMX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 10, 2017 at 8:30 AM Eastern Time. ...

  • Marketwired8 months ago

    Aevi Genomic Medicine to Host Conference Call to Announce First Quarter and Discuss Recent Business Updates

    Aevi Genomic Medicine, Inc. announced today it will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 8:30 a.m. EDT to report financial results for the first quarter and discuss ...

  • Marketwired8 months ago

    Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference

    Aevi Genomic Medicine, Inc. announced today that Michael F. Cola, President and Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017 at ...

  • Zacks Small Cap Research8 months ago

    GNMX: New SAGA Data May Be Just What The Doctor Ordered

    Aevi (GNMX) management indicated during the March 20th reveal of topline SAGA data, which showed the studies’ primary endpoint (i.e. As a reminder (and which is explained in further detail below), while SAGA data showed that the primary endpoint was not met, secondary analyses were quite positive.  This includes meeting statistical significance on the CGI-I secondary endpoint as well as on the ADHD-RS responder measure (prespecified as decrease of ADHD-RS score of 30% or more).  Additionally, the ADHD-RS inattention subscale (i.e.

  • Marketwired8 months ago

    Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

    ) (the Company) today announced updated responder data from a subset of genomically identified patients in the SAGA trial of AEVI-001 in adolescent Attention Deficit Hyperactivity Disorder (ADHD). The new data will be presented at the 6th World Congress on ADHD in Vancouver, Canada on April 21, 2017.

  • Marketwired8 months ago

    Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

    Aevi Genomic Medicine, Inc. today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6th World Congress on ADHD taking place April ...

  • Marketwired9 months ago

    Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference

    Aevi Genomic Medicine, Inc. announced today that Brian D. Piper, Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT at ...

  • Zacks Small Cap Research9 months ago

    GNMX: SAGA Misses Primary Endpoint But Data Warrants Optimism

    By Brian Marckx, CFA NASDAQ:GNMX SAGA Results: Primary Endpoint Missed But Data-Within-The-Data Suggest Reasons To Remain Optimistic Aevi Genomic Medicine (NASDAQ:GNMX) announced topline results of SAGA ...

  • Accesswire9 months ago

    Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine

    NEW YORK, NY / ACCESSWIRE / March 22, 2017 / The choice of technology a biotech company pursues can be critical to stock success and investor decision making. It is a general rule that the biotech sector ...

  • Why Aevi Genomic Medicine Got Crushed Today
    Motley Fool9 months ago

    Why Aevi Genomic Medicine Got Crushed Today

    The biotech's share price was cut in half after the company announced a failed clinical trial for its lead drug.

  • Marketwired9 months ago

    Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001

    PHILADELPHIA, PA-- - Trial did not meet primary endpoint , however showed encouraging trend in improvement at highest dose Strong trend of efficacy in ADHD-RS inattention subscale Clear signal of efficacy ...

  • Marketwired9 months ago

    Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference

    Aevi Genomic Medicine, Inc. announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22, 2017 at ...